Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Febuxostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 11/20 | 1.00 |
| ▸ | TARBP2 | Q15633 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | PPID | Q08752 | 1/20 | 0.67 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Febuxostat SCHEMBL30161803 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL249339 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL28271887 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935497 | 0.99 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935500 | 0.99 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL2635494 | 0.98 | XDH (0.96) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL437353 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL23417559 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL16363788 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL29183567 | 0.91 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| EP-4638847-A1 | KNITTING METHOD FOR PRODUCTION OF MOISTURE ABSORBENT QUICK-DRYING SINGLE-KNITTED FABRIC | Trans Pacific Textile (M) Sdn. Bhd. (MY) | 2025-10-29 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250052754-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, TREATMENT OF AND PREVENTION OF KIDNEY DISEASE | XORTX THERAPEUTICS, INC. (CA) | 2025-02-13 | — | — | US | disclosed |
| CN-119013415-A | Compositions and methods for diagnosis, treatment and prevention of kidney disease | 佐尔特斯医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3981469-B1 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | NIPPON CHEMIPHAR CO (JP) | 2024-11-20 | — | — | EP | disclosed |
| EP-4453235-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS, TREATMENT OF AND PREVENTION OF KIDNEY DISEASE | XORTX Therapeutics Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| CN-118549571-A | Method for separating and measuring content of related substances in febuxostat tablet by adopting HPLC (high Performance liquid chromatography) | 广州汇元医药科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118490656-A | Febuxostat tablet and preparation method thereof | 海南林恒制药股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-11607403-B2 | Methods and compositions for promoting adult neurogenesis | MORNINGSIDE VENTURES LIMITED (CN) | 2023-03-21 | — | — | US | disclosed |
| CN-115770226-A | Febuxostat tablet and preparation method thereof | 修正药业集团股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115531338-A | Febuxostat tablet and preparation method thereof | 成都恒瑞制药有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220323441-A1 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| CN-109152768-B | Methods and compositions for promoting adult neurogenesis | 晨兴生命科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4019048-A1 | ABCC11 INHIBITOR | The University of Tokyo (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220130553-A1 | METHOD FOR EXTRACTING RELATED DISEASE FROM PATIENT PRESCRIPTION AND PROVIDING EXTRACTED DISEASE RELATED INFORMATION | BAE HYOUNG JUN (KR) | 2022-04-28 | — | — | US | disclosed |
| EP-3981469-A1 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | Nippon Chemiphar Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| US-20220072022-A1 | ANTI-AGING AGENT OR LIFE-EXTENDING AGENT | STAGEN CO., LTD. (JP) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | XDH 2691/4885TARBP2 3639/4885ABCC4 2380/4885 |
| US-20220323441-A1 | THERAPEUTIC FOR GOUT OR HYPERURICEMIA | XDH, SLC10A1, TXN2 | XDH 1/4885TARBP2 3495/4885ABCC4 402/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | XDH 2691/4885TARBP2 3639/4885ABCC4 2380/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | XDH 2986/4885TARBP2 4084/4885ABCC4 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.